Navigation Links
Novel Small Molecule Therapy Shows Benefit for Anemic Patients Via Hydration of Red Blood Cells
Date:2/5/2008

nd markers of RBC destruction (hemolysis) in SCD patients. The investigators also sought to obtain additional safety data and identify the optimal dose for a phase III study. The primary efficacy endpoint was the change in blood hemoglobin level from baseline to end of study, and secondary endpoints included markers of hemolysis, changes in RBC count and indices, and frequency of painful events or "crises."

"An understanding of the pathophysiology of sickle cell disease is extremely important in order to identify new therapeutic targets," said Kenneth Ataga, MD, of the Division of Hematology/Oncology at the University of North Carolina at Chapel Hill and lead author of the study.

A total of 90 eligible patients were enrolled in the trial. Of these participants, 24 were also taking hydroxyurea, a drug already approved for the treatment of SCD. The patients were randomized into three treatment arms: placebo (n=30), low-dose senicapoc (6 mg/day, n=29), and high-dose senicapoc (10 mg/day, n=31). Safety and efficacy assessments were obtained at the end of week one and then every two weeks until completion of the study treatment.

Patients treated with senicapoc achieved measurable improvements in hemoglobin levels. Patients in the high-dose senicapoc arm achieved a hemoglobin increase of 0.68 g/dL (vs. 0.01 g/dL for patients taking placebo). The team also found corresponding increases in hematocrit and RBC count in the patients taking senicapoc when compared to placebo. Notably, the sub-groups of patients taking hydroxyurea achieved similar results. In the low-dose group, the increase in hemoglobin compared to placebo was not statistically significant.

Treatment with senicapoc also produced dose-dependent and statistically significant improvements in secondary endpoints, including the percentage of dense RBCs (-2.41 vs. -0.08, high-dose vs. placebo), reticulocytes (-4.12 vs. -0.46), and lactate dehydrogenase (-121 vs. -15), a marker of
'/>"/>

SOURCE American Society of Hematology
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CeNeRx BioPharma Announces Successful Completion of Phase l Clinical Program for Novel Antidepressant Agent Tyrima(TM)
2. First Patient Enrolled in Cogentus Pharmaceuticals Pivotal Phase 3 Trial of Novel Combination Medicine
3. Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF
4. Celldex Therapeutics Receives Fast-Track Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma
5. Novel Mechanism for Long-Term Learning Identified by Carnegie Mellon Researchers
6. Orion Genomics Announces the Discovery of Novel Breast Cancer Biomarkers
7. SuperGen Reports Initiation of Multi-arm Phase 1b Trial of Novel Tyrosine Kinase Inhibitor
8. PTC Therapeutics Presents Encouraging Phase 1 Results of its Novel VEGF Inhibitor, PTC299, at 30th Annual San Antonio Breast Cancer Symposium
9. Chroma Announces Positive Phase I Efficacy Data for Novel Cancer Therapy CHR-2797
10. Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel Selective Inhibitor of JAK2
11. Preclinical Studies Show Promise for Novel Antibody Therapy to Treat Acute Myeloid Leukemia (AML)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015  Valeant Pharmaceuticals International, Inc. ... closing of its previously announced registered offering of common ... (the "Offering"). Pursuant to the Offering, the Company issued ... share, for aggregate gross proceeds of approximately $1.45 billion. ... U.S. Securities and Exchange Commission a final prospectus supplement ...
(Date:3/27/2015)... DALLAS , March 27, 2015   ... global leader in biosimilars and the world,s leading ... two studies that support an evaluation of biosimilarity ... U.S. Food and Drug Administration (FDA) conditionally approved ... Amgen,s EPOGEN™ (epoetin alfa). These study data were ...
(Date:3/27/2015)... YORK , March 27, 2015  Delcath ... pharmaceutical and medical device company focused on oncology ... and metastatic liver cancers, announces the reporting of ... Company,s Melphalan Hydrochloride for Injection with the Delcath ... a poster presentation at the Society of Surgical ...
Breaking Medicine Technology:Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 2Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 3Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 2Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 4Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 5
... , RICHMOND, Calif., Oct. 13 Sangamo BioSciences, Inc. ... its previously announced public offering of 3,000,000 shares of ... share. The net proceeds to Sangamo from the sale ... and commissions and other estimated offering expenses, were approximately ...
... Accuray Incorporated (Nasdaq: ARAY ), a global leader ... is scheduled to present at the Oppenheimer Healthcare Conference in ... a.m. ET (6:40 a.m. PT). , A live webcast of ... page of the Company,s Web site at http://www.accuray.com ...
Cached Medicine Technology:Sangamo Announces Closing of Common Stock Offering 2Sangamo Announces Closing of Common Stock Offering 3Accuray Incorporated to Present at 20th Annual Oppenheimer Healthcare Conference 2
(Date:3/28/2015)... Early surgery may not be the best ... injuries, according to new research from Tripler Army Medical ... Society for Sports Medicine’s ( AOSSM ) Specialty Day, ... was not performed. , The final study group focused ... 17 receiving non-surgical therapy. Of the non-surgery group, 8 ...
(Date:3/28/2015)... 28, 2015 Healthpointe’s otolaryngologists, medical practitioners ... throat disorders, are now offering a wide variety ... which is characterized by the presence of phantom sounds ... people, tinnitus is a prevalent symptom that can arise ... is non-fatal, tinnitus can impede a person’s quality of ...
(Date:3/28/2015)... Servpro of Paso Robles , ... a report about the link between mold and asthma. ... according to recent medical research, may even cause asthma ... Environmental Protection Agency, people with sensitivity to mold or ... may trigger asthma attacks for asthma sufferers. The EPA ...
(Date:3/27/2015)... 2015 Florida Hospital is excited to continue ... exclusive health care provider for the 2015 and 2016 season. ... medical care and an athletic trainer for the team throughout ... its season against the Cleveland Gladiators at Amalie Arena; the ... extremely important to us as it gives us the opportunity, ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 Healthpointe is ... G. Katz, M.D., is now treating knee and hip ... Anaheim , Long Beach, and La Mirada. Dr. ... acute knee and hip joint disorders as well as ... is passionate in returning his patients back to their ...
Breaking Medicine News(10 mins):Health News:For Type V AC Joint Injuries, Early Surgery May Not Be the Best Approach 2Health News:Healthpointe now Offering Tinnitus Treatments in Clinics throughout Southern California 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 3Health News:Florida Hospital Is Kicking off the 2015 Season as the Exclusive Health Care Provider for the Tampa Bay Storm 2Health News:Florida Hospital Is Kicking off the 2015 Season as the Exclusive Health Care Provider for the Tampa Bay Storm 3Health News:Fellowship-Trained and Board-Certified Orthopedic Surgeon is Now Treating Knee and Hip Joint Disorders in Anaheim, California 2Health News:Fellowship-Trained and Board-Certified Orthopedic Surgeon is Now Treating Knee and Hip Joint Disorders in Anaheim, California 3
... Website for People Seeking Quality Care , ... Atlanta, ... is pleased to announce Adventist Midwest Health as one of its ... highly targeted search engine optimization campaign, and over the course of ...
... county Star awarded Dr. Khanna the reader,s choice award for Westlake village ... for the most popular and caring local business represented in the newspaper. ... ... county Star awarded Dr. Khanna the reader,s choice award for ...
... Systems signs multi-year agreement with PureWellness to provide comprehensive employee wellness ... ... 10, 2009 -- PureWellness, Inc, a leading provider of online wellness ... based in Plano, TX, to provide a comprehensive online wellness program ...
... that Guy,s and St Thomas, NHS Foundation Trust ... digital dictation workflow system, further enhancing the Trust,s ... a number of specialties. The success of replacing ... system within Oncology and Renal has led the ...
... given financial incentives to improve the quality of ... of changes important to advancing quality, according to ... adopted by medical groups include speeding up adoption ... more closely tracking the improvement of physician performance ...
... With Patient Safety Awareness WeekSOUTH BEND, Ind., March ... Week, Press Ganey Associates, Inc. today released a ... assess the correlation between medical errors and the ... The report establishes a baseline for future efforts ...
Cached Medicine News:Health News:Adventist Midwest Health Engages Medium Blue Search Engine Marketing in Geographically-Targeted SEO Campaign 2Health News:Adventist Midwest Health Engages Medium Blue Search Engine Marketing in Geographically-Targeted SEO Campaign 3Health News:Ventura County Star Newspaper Honors Khanna Institute 2Health News:Global Leader in Information Technology Services and Business Solutions Signs Long-Term Agreement with PureWellness 2Health News:Global Leader in Information Technology Services and Business Solutions Signs Long-Term Agreement with PureWellness 3Health News:Guy's and St Thomas' NHS Foundation Trust extends patient care benefits of BigHand Digital Dictation 2Health News:Study finds pay for performance stimulates changes in medical practice 2Health News:Study finds pay for performance stimulates changes in medical practice 3Health News:Press Ganey Releases Innovative Report to Assess Culture of Safety in U.S. Hospitals 2Health News:Press Ganey Releases Innovative Report to Assess Culture of Safety in U.S. Hospitals 3
BETADINE® Solution Swabsticks are indicated whenever a topical microbicide is applied most conveniently with a swabstick....
... contains 70% alcohol and 10% povidone ... base, forming a barrier on the ... environment for the povidone iodine, giving ... associated with catheter related infections for ...
... Aplicare's Saturated Swabsticks ... open, single-use foil-laminated pouches. ... is saturated with precisely ... solution. Each package is ...
... Swabsticks are packaged in easy open, single-use ... saturated with precisely the correct amount of ... the safest possible product for the patient. ... an excellent combination of ethyl alcohol and ...
Medicine Products: